Summary
The provided AI content correctly identifies and supports the NuvaRing boxed warning regarding cigarette smoking, including the contraindication for women over 35 who smoke, and accurately cites related warnings/precautions language.
Category Scores
Accurate Statements
Cigarette smoking increases the risk of serious cardiovascular events with NuvaRing (CHC use), and CHCs should not be used by women over 35 who smoke.
Supported by BOXED WARNING and reinforced by CONTRAINDICATIONS (includes 'Smoke, if over age 35') and Warnings/Precautions (5.1) discussion of increased thromboembolic/arterial risk with smoking and greatest risk in older (>35) smokers.
Unsupported Statements
None identified as unsupported relative to the supplied prescribing information for the smoking/cardiovascular claim.
All smoking-related claims in the provided AI response are explicitly supported by the boxed warning/contraindications/warnings excerpts supplied.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
No unsafe or contradictory statements regarding the smoking-related cardiovascular risk; the key boxed-warning contraindication (>35 and smoking) is accurately reflected.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement